Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:GALT NASDAQ:NMRA NASDAQ:XBIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.20+0.2%$2.72$0.87▼$6.14$323.37M0.99915,823 shs1.51 million shsGALTGalectin Therapeutics$4.98-4.0%$4.43$0.73▼$6.55$320.30M0.85389,654 shs195,895 shsNMRANeumora Therapeutics$1.78-3.5%$1.70$0.61▼$17.19$287.46M2.921.73 million shs342,156 shsXBITXBiotech$2.47-2.8%$2.89$2.35▼$8.32$75.31M0.8566,300 shs43,082 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+6.69%+3.57%+7.77%+91.02%-37.08%GALTGalectin Therapeutics+4.64%+9.49%+15.33%+79.58%+99.62%NMRANeumora Therapeutics+2.22%-5.15%+21.05%+7.60%-88.56%XBITXBiotech+1.20%-5.58%-6.62%-15.33%-65.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.20+0.2%$2.72$0.87▼$6.14$323.37M0.99915,823 shs1.51 million shsGALTGalectin Therapeutics$4.98-4.0%$4.43$0.73▼$6.55$320.30M0.85389,654 shs195,895 shsNMRANeumora Therapeutics$1.78-3.5%$1.70$0.61▼$17.19$287.46M2.921.73 million shs342,156 shsXBITXBiotech$2.47-2.8%$2.89$2.35▼$8.32$75.31M0.8566,300 shs43,082 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+6.69%+3.57%+7.77%+91.02%-37.08%GALTGalectin Therapeutics+4.64%+9.49%+15.33%+79.58%+99.62%NMRANeumora Therapeutics+2.22%-5.15%+21.05%+7.60%-88.56%XBITXBiotech+1.20%-5.58%-6.62%-15.33%-65.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$4.1730.33% UpsideGALTGalectin Therapeutics 2.00Hold$6.0020.46% UpsideNMRANeumora Therapeutics 2.00Hold$7.14302.41% UpsideXBITXBiotech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XBIT, NMRA, ALEC, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NMRANeumora TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025XBITXBiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NMRANeumora TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025XBITXBiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025ALECAlectorBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/16/2025NMRANeumora TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Underweight8/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$81.13M3.99N/AN/A$1.29 per share2.48GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AXBITXBiotechN/AN/AN/AN/A$5.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)XBITXBiotech-$38.53M-$0.92N/A∞N/AN/A-15.60%-14.64%11/12/2025 (Estimated)Latest XBIT, NMRA, ALEC, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GALTGalectin Therapeutics-$0.11N/AN/AN/AN/AN/A11/11/2025Q3 2025NMRANeumora Therapeutics-$0.34N/AN/AN/AN/AN/A11/5/2025Q3 2025ALECAlector-$0.40N/AN/AN/A$3.49 millionN/A8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/13/2025Q2 2025XBITXBiotechN/A-$0.06N/A-$0.06N/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38-$0.33+$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78GALTGalectin TherapeuticsN/A1.431.43NMRANeumora Therapeutics0.1110.5410.54XBITXBiotechN/A40.1640.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%GALTGalectin Therapeutics11.68%NMRANeumora Therapeutics47.65%XBITXBiotech55.70%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%GALTGalectin Therapeutics50.10%NMRANeumora Therapeutics26.80%XBITXBiotech30.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableGALTGalectin Therapeutics964.06 million31.97 millionOptionableNMRANeumora Therapeutics108161.95 million118.54 millionOptionableXBITXBiotech10030.49 million21.10 millionOptionableXBIT, NMRA, ALEC, and GALT HeadlinesRecent News About These CompaniesXBiotech (NASDAQ:XBIT) Share Price Crosses Below 50-Day Moving Average - Should You Sell?October 10, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (E+)" Rating for XBiotech (NASDAQ:XBIT)October 8, 2025 | marketbeat.comXBiotech (NASDAQ:XBIT) Stock Crosses Below 50 Day Moving Average - Here's What HappenedSeptember 23, 2025 | marketbeat.comShort Interest in XBiotech Inc. (NASDAQ:XBIT) Decreases By 45.3%September 16, 2025 | marketbeat.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insidersAugust 28, 2025 | finance.yahoo.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationMarch 2, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmMarch 1, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 28, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 27, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 26, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 25, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 24, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 23, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 22, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 21, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 20, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 18, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 17, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 16, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 15, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 14, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXBIT, NMRA, ALEC, and GALT Company DescriptionsAlector NASDAQ:ALEC$3.20 +0.01 (+0.22%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Galectin Therapeutics NASDAQ:GALT$4.98 -0.21 (-4.03%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Neumora Therapeutics NASDAQ:NMRA$1.78 -0.07 (-3.53%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.XBiotech NASDAQ:XBIT$2.47 -0.07 (-2.76%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
